Last reviewed · How we verify

MesenCure — Competitive Intelligence Brief

MesenCure (MesenCure) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy (mesenchymal stem cells). Area: Regenerative Medicine / Immunology.

phase 3 Cell therapy (mesenchymal stem cells) Regenerative Medicine / Immunology Biologic Live · refreshed every 30 min

Target snapshot

MesenCure (MesenCure) — BonusBio Group Ltd. MesenCure is a mesenchymal stem cell-based therapy designed to promote tissue regeneration and reduce inflammation through paracrine signaling.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MesenCure TARGET MesenCure BonusBio Group Ltd phase 3 Cell therapy (mesenchymal stem cells)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy (mesenchymal stem cells) class)

  1. BonusBio Group Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MesenCure — Competitive Intelligence Brief. https://druglandscape.com/ci/mesencure. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: